Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director
|
|
Foamix Pharmaceuticals Ltd. (FOMX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/07/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Quarterly results |
| 02/28/2019 |
8-K
| Quarterly results |
| 11/07/2018 |
8-K
| Quarterly results|
Docs:
|
"Rehovot, Israel, November 7, 2018",
"Presentation slides",
"Rehovot, Israel, and Bridgewater, NJ – November 7th, 2018 – Foamix Pharmaceuticals Ltd. , , a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced the topline results from its Phase 3 program evaluating FMX103 1.5% minocycline foam, in the treatment of moderate-to-severe papulopustular rosacea. Studies FX2016-11 and FX2016-12 met both co-primary endpoints of absolute change from baseline in inflammatory lesion count at Week 12, and Investigator Global Assessment treatment success at Week 12, defined as an IGA score of 0 or 1, and at least a 2-grade improvement from baseline. The safety profile of FMX103 was found to be favorable. Data from study FX2016-13 evaluating the..." |
|
| 05/09/2018 |
8-K
| Quarterly results |
|
|